deltatrials
Completed PHASE2 NCT01949051

A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis

A Randomized, Double-blind, Placebo Controlled, 3 Way Cross Over Study in Subjects With Allergic Rhinitis to Assess the Effect of Intranasal Repeat Doses of Levocabastine When Administered Once Daily or Twice Daily on the Symptoms of Rhinitis in an Allergen Challenge Chamber

Sponsor: GlaxoSmithKline

Conditions Rhinitis, Allergic, Perennial and Seasonal
Interventions Levocabastine Placebo
Updated 7 times since 2017 Last updated: May 9, 2017 Started: Oct 1, 2013 Primary completion: Feb 4, 2014 Completion: Feb 4, 2014

Listed as NCT01949051, this PHASE2 trial focuses on Rhinitis, Allergic, Perennial and Seasonal and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jul 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jul 2017 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Mississauga, Canada